The iLite® IL-12 assay provides functional, cell-based quantification of IL-12 signaling. Suited for immune pathway studies and evaluation of therapeutic cytokine modulators.

• High sensitivity and large dynamic range
• "Assay-ready" format for rapid and convenient use
• Reproducible and biologically relevant results
• Reduced assay variability and higher reproducibility compared to cells in culture
• Normalization of cell counts and serum matrix effects using a second reporter gene

 

Product Overview

iLite® IL-12 Assay Ready Cells are a genetically engineered reporter gene cell line line (DT-40, ATCC#CRL-2111) responsive to IL-12 by specific and proportional expression of Firefly Luciferase. They can be used for the quantification IL-12 or p40 inhibitor activity, and for detecting neutralizing antibody response against such inhibitors in human serum.

Normalization of cell counts, and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct under the control of a constitutive promotor.

iLite® IL-12 Assay Ready Cells are optimized to be used together with the iLite® IL-23 Assay Ready Cells, allowing testing for specific IL-12 inhibitory activity and screening for unwanted inhibitory activity of IL-23.

The ATCC® CRL-2111 cell line is used under a license from ATCC®

 

What's in the box?

>250µl of Assay Ready Cells suspended in cryoprotective medium.

 

Specifications

Product code	BM4012
Assay target	IL-12
Size	1 vial corresponding to one 96 well plate
Technology	Cell-based reporter gene assay
Detection system	Luminescence
Regulatory status	Research Use Only